ETAHX Mutual Fund

ETAHX Mutual Fund

NAV$51.69
See how much of ETAHX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Jun 30, 2026

Net Assets
$141M
Expense Ratio
1.56%
Dividend Yield (Current)
-
Holdings
92
Inception Date
Dec 27, 2012
Fund Family
Eventide
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+2.80%
1 Year+14.29%
3 Year+20.86%
5 Year+3.61%
10 Year+13.19%

Asset Allocation

Stocks: 90.58%
Bonds: 0.34%
Cash: 1.44%
Other: 7.65%
See how much of ETAHX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
GHGuardant Health, Inc5.37%
-Us Bank Mmda - Usbgfs 93.75%
MIRMMirum Pharmaceuticals, Inc.3.47%
KYMRKymera Therapeutics Inc3.22%
ABVXAbivax Sa-Adr2.94%
Top 10 Concentration: 32.43%Report Date: Jun 30, 2026
Download all 92 holdings for ETAHX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$4.35
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

ETAHX Mutual Fund Overview

ETAHX Mutual Fund (Eventide Healthcare & Life Sciences Fund Class A) is managed by Eventide with $141.4M in net assets. ETAHX expense ratio is 1.56%, holding 92 positions across sectors including Health Care. Inception date: 2012-12-27.

ETAHX performance shows a YTD return of 2.80%. The 1-year return is 14.29% and the 5-year return is 3.61%.

ETAHX top holdings include Guardant Health, Inc (5.4%), Us Bank Mmda - Usbgfs 9 (3.8%), Mirum Pharmaceuticals, Inc. (3.5%), Kymera Therapeutics Inc (3.2%), Abivax Sa-Adr (2.9%). Go to all ETAHX holdings, ETAHX sectors, or ETAHX dividends.

ETAHX can be compared against other funds. Use ETAHX overlap to find shared positions, or ETAHX vs another fund for a side-by-side view. ETAHX alternatives are available via the screener, along with tax-loss harvesting opportunities.